SAB Biotherapeutics is trading 5.7% higher at $3.15, with no confirmed company-specific catalyst identified for October 5, 2026. - The latest company announcement, dated October 1, said SAB-142 presentations will feature encore Phase 1 data at the Breakthrough T1D Clinical & Research Congress on October 9–11; it does not establish the reason for the move. - The S&P 500 and Nasdaq are higher, but available evidence does not show that broader market sentiment is driving the gain.